TuHURA Biosciences, Inc./NV (HURA): M&A transaction — TuHURA completes Kineta acquisition, adds Phase 2 VISTA mAb TBS-2025

TuHURA Biosciences, Inc./NV

Each Kineta share converted into 0.185298 TuHURA shares; ~2.87M shares issued at closing, plus up to ~1.13M additional shares subject to six-month adjustment.
VISTA-inhibiting antibody renamed TBS-2025; TuHURA plans Phase 2 trial in NPM1 mutated AML in 2H 2025.
Acquisition unlocks fourth tranche of $12.5M PIPE financing announced June 3, 2025.
TuHURA believes TBS-2025 can overcome acquired resistance to cancer immunotherapy; exploring ADC synergies.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

TuHURA Biosciences, Inc./NV completed an acquisition involving Kineta, Inc. for 0.185298 shares of TuHURA common stock per share, for an aggregate of approximately 2,868,169 shares of TuHURA Common Stock (closed 2025-06-30).

Action: acquisition
Counterparty: Kineta, Inc.
Consideration: 0.185298 shares of TuHURA common stock per share, for an aggregate of approximately 2,868,169 shares of TuHURA Common Stock
Closing: 2025-06-30

Exact text from the filing

share of Kineta common stock, par value $0.001 per share (each, a “Share”), issued and outstanding immediately prior to the First Merger, was converted into the right to receive 0.185298 shares of TuHURA common stock, par value $0.001 per share (“TuHURA Common Stock”), for an aggregate of approximately 2,868,169 shares of TuHURA Common Stock. Also pursuant to the

View on SEC.gov

8 m&a transactions filed in the last 30 days. Browse all m&a transactions →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-25-091693

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.